Vectus Biosystems (ASX:VBS) Other Current Liabilities: A$0.28 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:VBS Vectus Biosystems Ltd ASX:VBS
15 GF Score
Price A$0.18
! 2 Warning Signs
View Full Analysis

What is Vectus Biosystems Other Current Liabilities?

Vectus Biosystems ASX:VBS +9.38% 15 Other Current Liabilities is A$0.28 Mil as of Dec. 2025. GuruFocus rates ASX:VBS with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

Vectus Biosystems's other current liabilities for the quarter that ended in Dec. 2025 was A$0.28 Mil.

Vectus Biosystems's quarterly other current liabilities declined from Dec. 2024 (A$0.50 Mil) to Jun. 2025 (A$0.30 Mil) and declined from Jun. 2025 (A$0.30 Mil) to Dec. 2025 (A$0.28 Mil).

Vectus Biosystems's annual other current liabilities declined from Jun. 2023 (A$0.78 Mil) to Jun. 2024 (A$0.29 Mil) but then increased from Jun. 2024 (A$0.29 Mil) to Jun. 2025 (A$0.30 Mil).

Vectus Biosystems Other Current Liabilities Related Terms

Vectus Biosystems Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Vectus Biosystems's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vectus Biosystems Other Current Liabilities Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 1.30 0.78 0.29 0.30

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.29 0.50 0.30 0.28
ASX:VBS
15GF Score
Vectus Biosystems Ltd ASX:VBS
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vectus Biosystems Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of A$0.28 Mil mean?
Vectus Biosystems (ASX:VBS) has a Other Current Liabilities of A$0.28 Mil as of Dec. 2025. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vectus Biosystems.
Is Vectus Biosystems' Other Current Liabilities too high?
Vectus Biosystems' current Other Current Liabilities is A$0.28 Mil. Overall, Vectus Biosystems has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vectus Biosystems' Other Current Liabilities compare to VRTX and REGN?
Vectus Biosystems' Other Current Liabilities of A$0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Vectus Biosystems. Vectus Biosystems's current Other Current Liabilities is A$0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vectus Biosystems stock overvalued right now?
Vectus Biosystems (ASX:VBS) has a current Other Current Liabilities of A$0.28 Mil. The current Other Current Liabilities is A$0.28 Mil. Vectus Biosystems' overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Vectus Biosystems (ASX:VBS), the current Other Current Liabilities is A$0.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vectus Biosystems Business Description

Address 26-34 Dunning Avenue, Unit 5, Ground Floor, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company has developed and patented various novel compounds for the treatment of chronic fibrosis, including heart, kidney, liver, and lung fibrosis. Its drug candidate VB0004, is aimed at inhibiting and reversing the loss of functional tissue due to fibrosis, is in its human trials phase.
15GF Score

Get the complete analysis for ASX:VBS

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.18
Price